Bristol-Myers Squibb (NYSE: BMY) is a top healthcare company with a rich history that goes back to the 1800s. But its business, and its stock, have been underperforming recently.

Share prices of Bristol-Myers are down 11% over the past year, while the S&P 500 has been flat. And it's now trading near its 52-week low. Has this become a bargain stock to buy, or is there a valid reason for it to be trading at a discount?

A key reason investors haven't been too excited about Bristol-Myers' business is that the company's growth rate has typically been modest. And in its most recent quarter, for the first three months of the year, sales of $11.3 billion were down 3% year over year as top-selling drug Revlimid faced competition from generics.

Continue reading

Source Fool.com